|Bid||222.45 x 900|
|Ask||223.12 x 1000|
|Day's Range||222.45 - 226.00|
|52 Week Range||210.94 - 321.70|
|Beta (3Y Monthly)||0.59|
|PE Ratio (TTM)||88.23|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ICU Medical Inc NASDAQ/NGS:ICUIView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for ICUI with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.27 billion over the last one-month into ETFs that hold ICUI are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
ICU Medical (ICUI) delivered earnings and revenue surprises of 18.35% and 4.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Clemente, California-based company said it had profit of $1.44. Earnings, adjusted for one-time gains and costs, were $2.58 per share. The medical device maker posted revenue ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Vivek Jain has been the CEO of ICU Medical, Inc. (NASDAQ:ICUI) since 2014. This analysis a...
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q1 earnings. However, high long-term debt remains a concern.
Higher revenues, growth in APAC and strong operating margin benefit Baxter's (BAX) Q1 earnings. However, weak performance at Medication Delivery and Clinical Nutrition remains a concern.
Boston Scientific (BSX) is investing in new technologies and the global markets, which in turn, aids the uptick in sales across its most geographies in Q1.
Higher revenues, solid segmental performance and strong adjusted gross margins benefit Merit Medical's (MMSI) Q1 earnings. However, higher expenses remain a concern.
Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q1 earnings.
Quest Diagnostics (DGX) currently concentrates on its core diagnostic information services business and tries to maintain discipline in capital deployment.
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So before you...
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The healthcare business has suffered from product delays, stricter European regulations and two lost contracts in the United States. A plan to merge it with U.S.-based ICU Medical fell through in September because Smiths and ICU could not agree on terms. "Pursuing a demerger of Smiths Medical will lead to two stronger companies, each...maximising the opportunities in their respective markets," Chief Executive Andy Reynolds Smith said.
ICU Medical (ICUI) is well positioned to outperform the market, as it exhibits above-average growth in financials.